

Oman Diabetes Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

Oman's diabetes drugs and devices market size is estimated at USD 0.26 billion in the current year. The market is expected to reach USD 0.34 billion in five years, registering a CAGR of more than 5% during the forecast period.

The COVID-19 pandemic has positively impacted the Oman diabetes care equipment market growth. Diabetics infected with SARS-CoV-2 experience additional stress and increased secretion of hyperglycemic hormones, leading to elevated blood sugar levels, abnormal blood sugar fluctuations, and diabetic complications. Diabetes and uncontrolled hyperglycemia are risk factors for poor prognosis in COVID-19 patients, including increased risk of serious illness and death. To avoid complications, the patient's blood glucose level must be normal. Diabetic device makers are scrambling to ship devices to diabetics with the help of local governments during the COVID-19 crisis. The pandemic emergency has increased telemedicine by both patients and healthcare workers, removing many long-standing regulatory barriers.

Diabetes is associated with many health complications. People with diabetes need to make multiple corrections throughout the day to maintain nominal blood sugar levels, such as administering additional insulin or monitoring blood sugar levels and ingesting other carbohydrates.

Diabetes is a growing health burden nationwide and is a leading cause of premature death, morbidity, and loss of economic growth. Oman's Ministry of Health recently attended the virtual launch of the WHO Global Diabetes Compact, co-hosted by the World Health Organization and the Government of Canada. The compact aims to raise awareness of diabetes as a global disease and expand prevention and treatment as part of primary health care. Care and general health care.

Diabetes is an expensive chronic disease that requires medical devices to monitor blood sugar levels, according to the Oman

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Diabetes Association. This poses a challenge for low-income and social security patients, and efforts are being made to reduce the burden on these patients and promote carbohydrate restriction.

As part of an ODA initiative, Oman is trying to educate people with diabetes on the use of blood glucose meters. In addition, there are about 60 new pediatric infections per year. According to local studies and reports of reasonable diabetes control, the rate is 32-35% in adult patients but reaches 10-12% in children and adolescents. Governments are working to raise awareness of diabetes and increase access to blood glucose meters to improve diabetes management in children.

Based on the abovementioned factors, the market under study is expected to grow during the analysis period.

Oman Diabetes Drugs and Devices Market Trends

The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period

In CGM, a small sensor is inserted into the abdomen or arm, and a small plastic tube called a cannula is inserted into the top layer of skin. An adhesive patch holds the sensor in place, allowing it to measure glucose levels in interstitial fluid day and night. In general, the sensor should be replaced every 7-14 days. A small, reusable transmitter attached to the sensor allows the system to wirelessly transmit real-time readings to a monitor displaying blood glucose data. Some systems have their monitors, while others display information via smartphone apps.

The frequency of monitoring blood glucose levels depends on the type of diabetes and is different for each patient. People with type 1 diabetes should have their blood sugar checked regularly, monitor their blood sugar levels, and adjust their insulin dosage accordingly. His CGM device now details blood glucose patterns and trends compared to routine blood glucose monitoring at set intervals. In addition, current continuous blood glucose monitors can retroactively check blood glucose trends by downloading data or providing real-time images of blood glucose levels via the receiver display.

Continuous glucose monitoring sensors use glucose oxidase to measure blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxide, which reacts with platinum in the sensor to send an electrical signal to a transmitter. The sensor is the most important part of any continuous blood glucose monitoring device. Technological advances in improving sensor accuracy are expected to drive the growth of the segment during the forecast period.

Rising diabetes prevalence in Oman driving the market in the forecast year

According to the Oman Diabetes Association, diabetes is an expensive chronic disease requiring blood sugar level control. This poses a challenge for low-income and social security patients, and efforts are being made to reduce the burden on these patients and promote carbohydrate restriction. In addition, there are about 60 new pediatric infections per year. According to local studies and reports of good diabetes control, the rate is 32-35% in adult patients but reaches 10-12% in children and adolescents. Governments are committed to raising awareness of diabetes and increasing access to medicines to improve diabetes management.

Diabetes shortens life, and people with the disease are more likely to go blind and be hospitalized for amputations, kidney failure, heart attack, stroke, and heart failure. Metformin is the first-line treatment for hyperglycemia in T2DM. Metformin is not only an essential hypoglycemic agent but also has important anti-inflammatory properties. Other options should be considered if metformin is contraindicated or not tolerated or if treatment goals are not achieved after three months of maximum tolerated dose. Dipeptidyl peptidase four inhibitors, sodium glucose cotransporter two inhibitors, and glucagon-like peptide one agonist are commonly used as adjuncts to metformin treatment.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The Ministry of Health, Oman is strategically planning to contain the growing burden of diabetes and invest in all means to control it, stating that their work needs to ensure equitable and affordable access to treatment, and it is essential that they advocate for investments in diabetes education and prevention programs in Oman. Risk factors such as insufficient physical activity and the consumption of unhealthy diets are contributing to the development and progression of the disease.

The increasing diabetes prevalence and the above factors will likely drive segment growth over the forecast period.

Oman Diabetes Drugs and Devices Industry Overview

In order to survive in the market, manufacturers have constantly innovated. Large companies like Abbott and Medtronic have made numerous mergers, acquisitions and partnerships to gain market dominance while adhering to organic growth strategies. Manufacturers of insulin dosing devices spend a lot of money on R&D of the drugs and devices.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Table of Contents:

1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Dynamics
 - 4.2.1 Market Drivers
 - 4.2.2 Market Restraints
- 4.3 Porter's Five Forces Analysis
 - 4.3.1 Bargaining Power of Suppliers
 - 4.3.2 Bargaining Power of Consumers
 - 4.3.3 Threat of New Entrants
 - 4.3.4 Threat of Substitute Products and Services
 - 4.3.5 Intensity of Competitive Rivalry

5 Market Segmentation (Market Size by Value - USD)

- 5.1 Devices
 - 5.1.1 Monitoring Devices
 - 5.1.1.1 Self-monitoring Blood Glucose Devices
 - 5.1.1.2 Continuous Blood Glucose Monitoring
 - 5.1.2 Management Devices
 - 5.1.2.1 Insulin Pump
 - 5.1.2.2 Insulin Syringes

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.2.3 Insulin Cartridges
- 5.1.2.4 Disposable Pens
- 5.2 Drugs
 - 5.2.1 Oral Anti-Diabetes Drugs
 - 5.2.2 Insulin Drugs
 - 5.2.3 Combination Drugs
 - 5.2.4 Non-Insulin Injectable Drugs

6 Market Indicators

- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population

7 COMPETITIVE LANDSCAPE

- 7.1 Company Profiles
 - 7.1.1 Novo Nordisk
 - 7.1.2 Medtronic
 - 7.1.3 Insulet
 - 7.1.4 Tandem
 - 7.1.5 Ypsomed
 - 7.1.6 Novartis
 - 7.1.7 Sanofi
 - 7.1.8 Eli Lilly
 - 7.1.9 Abbott
 - 7.1.10 Roche
 - 7.1.11 AstraZeneca
 - 7.1.12 Dexcom
 - 7.1.13 Pfizer
- 7.2 Company Share Analysis

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Oman Diabetes Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

